The data indicated that IGF2BP3 might be associated with chemoresistance of specific chemotherapeutic agents, such as Trametinib, Cobimetinib, ARRY-162 and Selumetinib, which were commonly used MEK inhibitors approved by the FDA for cancer therapy. This evidence concerns the gene IGF2BP3 and cancer.